Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Key facts

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Principal Investigator

Sergio Amadori, MD

Ospedale Sant' Eugenio

Intervention

cytarabine(drug)

Enrollment

106 enrolled

Eligibility

61 years · All sexes

Timeline

2000

Study locations (18)

• Innsbruck Universitaetsklinik, Innsbruck, Austria
• A.Z. St. Jan, Bruges, Belgium
• Universitair Ziekenhuis Antwerpen, Edegem, Belgium
• CHU Sart-Tilman, Liège, Belgium
• University Hospital Rebro, Zagreb, Croatia
• Hopital Edouard Herriot, Lyon, France
• Hotel Dieu de Paris, Paris, France
• Hopital Necker, Paris, France
• Medizinische Klinik und Poliklinik, Heidelberg, Germany
• Eberhard Karls Universitaet, Tübingen, Germany
• Ospedale Generale Regionale, Bolzano, Italy
• Ospedali Riuniti, Reggio Calabria, Italy
• Ospedale San Eugenio, Rome, Italy
• Azienda Policlinico Umberto Primo, Rome, Italy
• Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy
• +3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT00658814
  Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
  National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →